May 6, 3:35 PMVaccines ExaminerNorma Erickson
September 2008, after a year-long battle with rival pharmaceutical company (Merck, manufacturer of Gardasil), GlaxoSmithKline was awarded the contract to provide its HPV vaccine, Cervarix, to all girls between the ages of 12 and 18 in the United Kingdom.
Stacey, and her family, are wishing they never heard of Cervarix. Before Cervarix, Stacy was a happy-go-lucky girl who went out of her way to help others. In addition to her busy school schedule, she had a part-time job at the local market. She also did volunteer work two days each week at a school where the children loved her. Now all of that is over.
Stacey had no history of medical problems, according to her physician. She was a normal, happy and healthy girl until after she completed the three recommended doses of Cervarix, the same HPV vaccine offered to all school girls age 12 to 18 in the United Kingdom.
Stacey received Carvarix injections in November 2008, January 2009 and the 16th of May 2009. When she became increasingly emotional after the first two injections, her parents thought their easy-going, 17-year old daughter had finally succumbed to adolescent mood swings. They were mistaken.
Immediately after her third injection, Stacey had a much more violent reaction. Four days later, Stacey suffered her first epileptic seizure, followed by 17 more in the following week.